Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 4
2018 4
2019 8
2020 11
2021 8
2022 5
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16.
Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, Benard E, Kaveh F, Caulier B, Helgestad Gjerde C, García de Jalón E, Warren DJ, Lindemann K, Rokkones E, Davidson B, Myhre MR, Kvalheim G, Bjørge L, McCormack E, Inderberg EM, Wälchli S. Casey NP, et al. Among authors: inderberg em. J Immunother Cancer. 2024 Apr 11;12(4):e008179. doi: 10.1136/jitc-2023-008179. J Immunother Cancer. 2024. PMID: 38604812 Free PMC article.
Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer.
Maggadottir SM, Dueland S, Mensali N, Hamre H, Andresen PA, Myhre MR, Juul HV, Bigalke I, Lundby M, Hønnåshagen TK, Sæbøe-Larssen S, Josefsen D, Hagtvedt T, Wälchli S, Kvalheim G, Inderberg EM. Maggadottir SM, et al. Among authors: inderberg em. Mol Ther. 2024 Apr 6:S1525-0016(24)00225-9. doi: 10.1016/j.ymthe.2024.04.009. Online ahead of print. Mol Ther. 2024. PMID: 38582964 Free article.
In vitro re-challenge of CAR T cells.
Klee CH, Villatoro A, Casey NP, Inderberg EM, Wälchli S. Klee CH, et al. Among authors: inderberg em. Methods Cell Biol. 2024;183:335-353. doi: 10.1016/bs.mcb.2023.06.003. Epub 2023 Sep 15. Methods Cell Biol. 2024. PMID: 38548418
WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy.
Fløisand Y, Remberger M, Bigalke I, Josefsen D, Vålerhaugen H, Inderberg EM, Olaussen RW, Gjertsen BT, Goedkoop R, Geiger C, Prinz PU, Schnorfeil FM, Pinkernell K, Schendel DJ, Kvalheim G. Fløisand Y, et al. Among authors: inderberg em. Leukemia. 2023 Sep;37(9):1842-1849. doi: 10.1038/s41375-023-01980-3. Epub 2023 Jul 28. Leukemia. 2023. PMID: 37507426
Determination of CAR T cell metabolism in an optimized protocol.
Joaquina S, Forcados C, Caulier B, Inderberg EM, Wälchli S. Joaquina S, et al. Among authors: inderberg em. Front Bioeng Biotechnol. 2023 Jun 20;11:1207576. doi: 10.3389/fbioe.2023.1207576. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 37409169 Free PMC article.
ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.
Mensali N, Köksal H, Joaquina S, Wernhoff P, Casey NP, Romecin P, Panisello C, Rodriguez R, Vimeux L, Juzeniene A, Myhre MR, Fåne A, Ramírez CC, Maggadottir SM, Duru AD, Georgoudaki AM, Grad I, Maturana AD, Gaudernack G, Kvalheim G, Carcaboso AM, de Alava E, Donnadieu E, Bruland ØS, Menendez P, Inderberg EM, Wälchli S. Mensali N, et al. Among authors: inderberg em. Nat Commun. 2023 Jun 8;14(1):3375. doi: 10.1038/s41467-023-39097-x. Nat Commun. 2023. PMID: 37291203 Free PMC article.
Efficient chimeric antigen receptor targeting of a central epitope of CD22.
Casey NP, Klee CH, Fåne A, Caulier B, Graczyk-Jarzynka A, Krawczyk M, Fidyt K, Josefsson SE, Köksal H, Dillard P, Patkowska E, Firczuk M, Smeland EB, Winiarska M, Myklebust JH, Inderberg EM, Wälchli S. Casey NP, et al. Among authors: inderberg em. J Biol Chem. 2023 Jul;299(7):104883. doi: 10.1016/j.jbc.2023.104883. Epub 2023 Jun 1. J Biol Chem. 2023. PMID: 37269947 Free PMC article.
A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT).
Maggadóttir SM, Kvalheim G, Wernhoff P, Sæbøe-Larssen S, Revheim ME, Josefsen D, Wälchli S, Helland Å, Inderberg EM. Maggadóttir SM, et al. Among authors: inderberg em. Front Oncol. 2022 Nov 10;12:1031232. doi: 10.3389/fonc.2022.1031232. eCollection 2022. Front Oncol. 2022. PMID: 36439452 Free PMC article.
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
Ellingsen EB, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, Guren T, Clancy T, Mezheyeuski A, Inderberg EM, Mangsbo SM, Binder M, Hovig E, Gaudernack G. Ellingsen EB, et al. Among authors: inderberg em. J Transl Med. 2022 Sep 11;20(1):419. doi: 10.1186/s12967-022-03624-z. J Transl Med. 2022. PMID: 36089578 Free PMC article. Clinical Trial.
44 results